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1. Introduction 
Diabetic retinopathy is a leading cause of adult vision loss and blindness. Angioprotective 
drugs are one of possibilities, which can be used in treatment of diabetic retinopathy. Nearly 
all of them are very efficient antioxidants or reactive oxygen and nitrogen species (RONS) 
scavengers. They often contain phenolic groups. Most of them are glycosides of plant origin 
with aglycones of flavonoid structure, i.e. aglycones are polyhydroxylated derivatives of 2-
phenyl-4H-chromen-2-one or 2-phenyl-4H-1-benzopyran-4-one. Quercetin, which is the 
aglycone of many glycosides including rutoside, can serve as a typical example. Other 
glycosides, such as a saponoside escine (Reparil®) isolated from seeds of horse chestnut 
Aesculus hippocastaneum, have triterpenic aglycones. (In fact, escin is a mixture of several 
related compounds. The particular structure on the Figure I express escin I that is a mixture 
of two geometric isomers. They differ in E or Z configuration of 2-methylbut-2-enoyl, which 
is attached to originally hydroxyl oxygen in position 21 of the triterpenoid scaffold.) (Kim 
et al., 2004, Carrasco  Vidrio, 2007). Flavonoid glycosides have poor bioavailability that is 
due to their low lipophilicity. This problem has been solved by etherification of phenolic 
groups of flavonoid aglycones with hydroxyalkyl such as hydroxyethyl groups (troxerutin) 
in past (Agolini  Cavallini, 1987, Wadworth  Faulds, 1992) Troxerutin was demonstrated 
to attenuate neovascularization in retinopathy in streptozocin-induced diabetic rats (Chung 
et al., 2005). More recently, increased bioavailability of flavonoid glycosides is reached by 
micronisation without changing their chemical structures. Preparations such as Detralex® or 
Daflon® contain standardized and micronized flavonoid fraction characterized by its 
content of diosmin, which is their main active constituent. Their activity in the treatment of 
diabetic retinopathy was clearly demonstrated (Lacombe et al., 1989). There is nearly only 
one exception among these quite complex compounds: calcium dobesilate (Danium ®, 
Doxium ®, Dexium®), which is a very simple synthetic molecule: calcium 2,5-
dihydroxybenzenesulfonate (see Figure 1) 
Calcium dobesilate is also almost the only one angioprotective drug that recently remains 
the object of interest in treatment of diabetic retinopathy including clinical studies (Leal et 
al. 2010, Einarsdottir & Stefansson, 2009, Ribeiro et al., 2006), and even it was used as a 
standard for determination of the particular activity of a traditional Chinese herbal medicine 
preparation (Luo et al. 2009).  
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Fig. 1. Calcium dobesilate as the simplest structure among angioprotective drugs. 
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2. Calcium dobesilate: Chemical, historical and bibliographical data 
2.1 Early syntheses of 2,5-dihydroxybenzenesulfonic acid and its salts 
The first synthesis of 2,5-dihydroxybenzenesulfonic acid that can be found is that in the article 
of Seyda (Seyda, 1883). On principle it was sulfonation of hydroquinone with diluted sulfuric 
acid in mild conditions, the reaction temperature did not exceed 50°C, for 3 hours. During this 
period, starting hydroquinone gradually dissolved in diluted sulfuric acid. After cooling of the 
solution for 24 hours, formed crystals of 2,5-dihydroxybenzenesulfonic acid were filtered off. 
The filtrate was diluted with water and under boiling saturated with barium carbonate. The 
excessive barium carbonate was then together with formed barium sulfate filtered off. The 
filtrate was being concentrated in vacuo until a white crystalline syrupy mass was formed. This 
viscous liquid was then poured on a porous ceramic plate to be dried. Thus barium 2,5-
dihydroxybenzenesulfonate was yielded. Potassium 2,5-dihydroxybenzenesulfonate was 
prepared by adding of potassium carbonate into an aqueous solution of barium 2,5-
dihydroxybenzenesulfonate followed by filtering-off of formed barium carbonate and 
concentration of the filtrate in vacuo into a viscous liquid that was then diluted with double 
volume of absolute ethanol. A brown precipitate, which had been formed was then filtered off 
and all the ethanol was distilled off from the filtrate with exclusion of air. Crystalline mass 
formed from the filtrate was then recrystallized from water to give transparent octaedric 
crystals. Sodium 2,5-dihydroxybenzenesulfonate was prepared similarly by adding of sodium 
carbonate into a solution of the barium salt. It was formed in the concentrated aqueous 
solution as a mass consisted from microscopic octaedric crystals. Lead 2,5-
dihydroxybenzesulfonate was prepared from the crude 2,5-dihydroxybenzenesulfonic acid 
and lead carbonate. It precipitated from a concentrated aqueous solution as an amorphous 
solid that was no more soluble in water. However, it was soluble in concentrated acetic acid. 
The lead salt gave the free 2,5-dihydroxybenzenesulfonic acid by reaction with sulfane (see 
Figure 2). 
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Fig 2. Early syntheses of 2,5-dihydroxybenzenesulfonic acid and some its metallic salts. 
2.2 Industrial „redox“ one-pot synthesis of calcium dobesilate vs. sulfonation 
followed by neutralization 
Estéve-Subirana (Estéve-Subirana, 1970) has developed a different synthesis of calcium 
dobesilate, which is also simple and suitable for the industrial production of it. It consists of 
only one reaction of calcium hydrogensulfite with 1,4-benzoquinone. Such a procedure 
could be classified as a „redox substitution“ due to changes of the oxidation states of both 
sulfur atom and benzene ring. However, such a synthesis is not suitable for low scale 
www.intechopen.com
 
Diabetic Retinopathy 
 
308 
preparations of calcium dobesilate including those that are performed by students in 
practical classes in subjects such as medicinal or organic chemistry. These practical 
educations can be met by students of fields such as pharmacy or chemistry at appropriate 
schools or faculties. The main problem of the Estéve-Subirana's procedure consists in use of 
calcium hydrogensulfite, which is not commercially available in solid state. Its concentrated 
aqueous solution is frequently prepared by reaction of gaseous sulfur dioxide with an 
aqueous suspension of calcium carbonate. This reaction can proceed in a special bubble 
column reactor typical for industrial processes such as the procedure developed by Rückauf 
and colleagues (Rückauf et al., 1990). 
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Fig. 3. Preparation of calcium dobesilate according to Estéve-Subirana (Estéve-Subirana, 
1970) preceeded with preparation of calcium hydrogensulfite according to Rückauf et al. 
(Rückauf et al. , 1990). 
To develop a simple and effective synthesis of calcium dobesilate that does not require 
calcium hydrogensulfite, we returned to sulfonation of hydroquinone. After we had tried 
several procedures using diluted sulfuric acid without significant successes (Šablatura, 
2005), we came back to the original preparation of Seyda (Seyda, 1883). We modified his 
synthesis of barium 2,5-dihydroxybenzenesulfonate for preparation calcium dobesilate in 
conditions of today. Hydroquinone was sulfonated with concentrated sulfuric acid, a 
resulted mixture was then neutralized short boiling with calcium carbonate. Poorly soluble 
calcium sulfate precipitate was then filtered off. The filtrate was evaporated nearly to 
dryness. The residuum was disperged in concentated ethanol and filtered. The ethanolic 
filtrate was evaporated to dryness. Recrystallization of the residuum from the mixture 
butan-1-ol / chloroform gave calcium dobesilate in the form of its monohydrate (see Fig. 4). 
Crystallization trials from several with various ratios alcohol / water mixtures led in most to 
solid solvates, e.g. calcium dobesilate : propan-2-ol 1 : 1.3 (dobesilate : alcohol ratio was 
estimated from 1H-NMR spectrum). Simple confirmation of identity of the product by 
determination of its melting point is impossible because of high value of its melting 
temperature, but it can be identified by simple spectrophotometry in UV region according to 
Czech Pharmacopoeia 2005 Edition (Czech Pharmacopoeia 2009, 2009) (see also bellow). 
This procedure was published in a journal devoted to chemical education (Farsa  
Šablatura, 2008) and in more detailed and modified form also in an instruction manual for 
practical courses in medicinal chemistry (Beneš  Farsa, 2007). It is notable that, short time 
after its publishing, very similar procedures of preparation of calcium dobesilate appeared 
in Chinese patents (Yao 2010, Yang et al. 2010). 
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Fig. 4. Preparation of calcium dobesilate proposed for practical courses in chemical 
disciplines 
2.3 Spectral data and other important physico-chemical properties of calcium 
dobesilate 
Infrared spectra of calcium dobesilate measured in a potassium bromide tablet contained 
significant absorption bands at wawenumbers 3410, 1500, 1470, 1220, 1080, 880, 815 and 640 
cm-1 (Estéve-Soler, 1977) A 1H nuclear magnetic resonance spectrum (1H-NMR) of calcium 
dobesilate recorded in deuterium oxide contained following signals (values of chemical 
shifts  are in ppm): 7.13 (bs, 3H, aromatic hydrogens), 6.70 (s, 2H, 2 OH) and 4.75 (s, 2H, 
H2O). The least signal served also as the reference one. There was evident from the ratio of 
integral areas that the investigated sample was calcium dobesilate monohydrate (Estéve-
Soler, 1977). 1H-NMR measured by the author in deuterated dimethyl sulfoxide (DMSO-D6) 
was a little different. It contained the following signals (chemical shifts  are in ppm, 
coupling constants J in Hz): 9.78 (s, 1H, OH), 8.84 (s, 1H, OH), 6.80 (d, 1H, J=2.4, arom. H), 
6.57 (m, 2H, arom. H), 3.37 (s, 4H, 2 H2O). The integral area of the signal assigned to water 
hydrogens corresponded to 4 hydrogen atoms per one dobesilate anion so that this sample 
was calcium dobesilate tetrahydrate (see Fig. 5). A 13C nuclear magnetic resonance spectrum 
(13C-NMR) of the same sample of calcium dobesilate was recorded by the author also in 
DMSO-D6 in attached proton test (APT) mode. This type of carbon NMR spectrum enables 
to differ between carbon atoms with odd and even number of hydrogen atoms attached to 
every particular carbon atom so that  in our case to distinguish between aromatic carbons 
with one hydrogen and those with no hydrogen. It contained the following signals (the 
values of chemical shift in ppm): 148.8 (CH), 145.8 (CH), 130.6 (CH), 117.9 (CSO3-), 116, 5 
(COH), 112.8 (COH) (see Fig. 5). 
Also ultraviolet spectra, which are advantageous namely for purity determination, have 
been known for decades. They have been recorded from various solvents such as water, 
methanol or aqueous hydrochloric acid. (Negritescu et al., 1979, Kračmár et al., 1988, Chen  
Xiao, 2008). These electronic spectra are relatively easy to obtain because of low prices of 
needed UV spectrophotometers in comparison with NMR or IR spectrometers. This is 
probably one of the reasons for which some pharmacopoeias use this method for 
confirmation of identity of calcium dobesilate monohydrate, which is official as a drug 
substance (Czech Pharmacopoeia 2009, 2009, European Pharmacopoeia Edition 7.2, 2011). In 
accordance with both pharmacopoeias, the UV spectrum of calcium dobesilate measured in 
water can have absorption maxima at 221 and 301 nm and the specific absorbance at 301 nm 
in the range 174 to 181 (see Fig. 6). 
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Fig. 5. 1H-NMR spectrum of calcium dobesilate dihydrate recorded at 200 MHz Varian 
Gemini FT-NMR spectrometer in DMSO-D6 solution (top) and its 13C-NMR spectrum  
measured in DMSO-D6 solution at 50 MHz at the same instrument (bottom). 
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Fig. 6. Ultraviolet spectrum of calcium dobesilate measured in an aqueous solution at 
Agilent 8453 diode array UV-VIS spectrophotometer in accordance with requirements of the 
European Pharmacopoeia (European Pharmacopoeia Edition 7.2, 2011). 
As it was mentioned above, melting point of calcium dobesilate monohydrate is out of range 
of measurement of common melting point apparatuses and thus it is not suitable for 
identification of calcium dobesilate monohydrate as a substance. Milne states that 
anhydrous calcium dobesilate melts above 300°C under decomposition (Milne, 2002).  
The pharmacopoeias state that calcium dobesilate monohydrate is very soluble in water, freely 
soluble in anhydrous ethanol, very slightly soluble in propan-2-ol and practically insoluble in 
dichloromethane (Czech Pharmacopoeia 2009, 2009, European Pharmacopoeia Edition 7.2, 
2011). In fact, it is extremely soluble in water: three weight parts of calcium dobesilate 
monohydrate dissolve in one part of boiling water. This ratio of the compound and the solvent 
can be used for purifying of the drug by recrystallization (Nováček et al., 1987). 
Since calcium dobesilate is a hydroquinone derivative it can be easily oxidized into calcium 
3,6-dioxocyclohexa-1,4-diene-1-sulfonate (see Fig. 7). 
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Fig. 7. Reversible oxidation of dobesilate anion into 3,6-dioxocyclohexa-1,4-diene-1-
sulfonate. 
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Reversibility of this reaction has been repeatedly demonstrated by cyclic voltammetry with 
various types of electrodes. (Zheng et al., 2007, Zhang  Zhang, 2009, Zhang et al., 2011). 
Such methods have reached very low detection limit for calcium dobesilate up to 4.0 × 10-8 
mol L-1 and have been resistant to interference with other reducing compounds occurring in 
body liquids such as uric acid, serotonin, and ascorbic acid (Hu et al., 2009). That is why 
they have been successfully used not only for identification and assay of calcium dobesilate 
in substance samples and drug formulations (Guangzhi et al., 2009) but also in biological 
samples (Zheng et al., 2007). The influence of bovine serum albumin (BSA) on the 
electrochemical behavior of calcium dobesilate was also investigated. The stoichiometric 
coefficient and the association constant of calcium dobesilate with BSA were obtained by 
this technique in addition to those obtained by UV-spectrophotometry. It was found that the 
peak currents in cyclic voltammetry diagrams decreased and the peak potentials stayed 
almost unchanged in the presence of BSA, indicating that there might exist an interaction 
between calcium dobesilate and BSA (Xu et al., 2009). Oxidation of calcium dobesilate is also 
used for its titrimetric assay by means of cerimetry with potentiometric end-point 
determination required by some pharmacopoeias (European Pharmacopoeia 7.2, 2011, 
Czech Pharmacopoeia 2009, 2009). This method gives more accurate results than 
chelatometric titrimetry using N,N’-ethylenediaminetetraacetic acid (EDTA) for 
complexation of calcium ion of calcium dobesilate (Zhang  Xu, 1999). The activity of 
calcium dobesilate as a reduction agent is also reason of its radical-scavenging activity, 
which plays an important role in its mechanism of action as a drug of diabetic retinopathy 
(see further).  
The chromatographic behaviour of calcium dobesilate is determined by its extremely low 
lipophilicity as it is an ionic salt. Thin-layer chromatography (TLC) on a silica gel normal 
phase was being used for identification of hydroquinone as an impurity in calcium 
dobesilate substance. While hydroquinone migrates in the required mobile phase 
dichloromethane : methyl acetate : ethyl acetate 20 : 30 : 50, calcium dobesilate remains at 
the start (Czech Pharmacopoeia 2002, 2002, Šablatura, 2006). Reversed phase high 
performance liquid chromatography (reversed phase-high performance liquid 
chromatography) methods for identification and content assay of calcium dobesilate namely 
in various samples have been reported. Assays of calcium dobesilate in dog blood plasma 
for pharmacokinetic purposes after its single (Plessas et al., 1986a) and repeated (Plessas et 
al., 1986b) administration were performed using a C18 column. A similar method using a 
Hypersil® octadecylsilyl silica gel (ODS) column and UV detection in absorption maximum 
of calcium dobesilate at 301 nm with mobile phase methanol : water 7 : 3 and flow rate 1.0 
mL min-1 has been developed for determination of calcium dobesilate in pharmaceuticals 
(Zhu  Chen, 2005). Slightly different conditions, mobile phase acetonitrile : water buffer 
pH 2.5 1 : 1, flow rate 1.0 mL min-1 and detection wavelength 290 nm, were used in a 
procedure suitable for simultaneous determination of calcium dobesilate and lidocaine 
hydrochloride, dexamethasone acetate, butylhydroxyanisol and hydroquinone as a 
degradation product of calcium dobesilate in suppositories and an ointment. The retention 
times ranged between 2.4 min for the most hydrophilic calcium dobesilate to 17.1 min for 
the most hydrophilic BHA (Zivanovic et al., 2005). Also recent pharmacopoeias utilize 
reversed phase-high performance liquid chromatography using a spherical end-capped 
ODS column, mobile phase acetonitrile : aqueous buffer solution 1 : 9, flow rate 0.8 mL min-1 
and detection wavelength 220 nm for the test for presence of impurities, namely 
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hydroquinone. calcium dobesilate could have the retention time about 6 min in this system 
(European Pharmacopoeia 7.2, 2011, Czech Pharmacopoeia 2009, 2009). Finally, Rona and 
Ary reported a reversed phase-high performance liquid chromatography procedure suitable 
for determination of calcium dobesilate in human plasma for purposes of bioequivalence 
studies. They used a C16 reverse phase modified with inserted amide moiety. Such phases 
have been recommended as suitable for separation of polar compounds (Sigma-Aldrich, 
2011). The mixture phosphate buffer pH 2.5 : acetonitrile 3 : 1 was used as a mobile phase, 
the detection wavelength was 305 nm (Rona  Ary, 2001). It is interesting that no high 
performance liquid chromatography procedure using electrochemical detection has been 
reported although redox properties of calcium dobesilate offer this possibility of sensitive 
detection. 
2.4 Polymorphism, solvate complexes and co-crystals of calcium dobesilate 
Calcium dobesilate monohydrate is the most common crystalline form of calcium dobesilate 
and is also official in many pharmacopoeias. It is also a subject of a mild misunderstanding 
between some pharmacopoeias and Chemical Abstracts or their electronic version, the data 
base SciFinder, because the Chemical Abstracts Service reference number (CAS RN) 20123-
80-2 is in the pharmacopoeias (European Pharmacopoeia 7.2, 2011, Czech Pharmacopoeia 
2009, 2009) assigned to this monohydrate while in SciFinder to anhydrous calcium 
dobesilate. Calcium dobesilate monohydrate is then referred in SciFinder under CAS RN 
117552-79-1 (SciFinder, 2011). Calcium dobesilate monohydrate has been characterized by 
powder X-ray diffraction spectrum (Lu, 2005) and by two methods of differential thermal 
analysis (DTA); thermogravimetric analysis (TGA) a differential scanning calorimetry 
(DSC). Caproiu and colleagues reported based on DTA that calcium dobesilate 
monohydrate showed dehydration starting at 115°C and ending at 180°C (Caproiu et al., 
1988) while Lu stated the dehydration interval between 134°C and 180°C (Lu, 2005). 
Calcium dobesilate dihydrate, sesquihydrate, i.e. hydrate containing 1.5 mol water per 1 mol 
calcium dobesilate, and non-stoichiometric hydrates containing 5/7, 5/4, 1.6 and 2.6 mol 
water per 1 mol calcium dobesilate respectively have been patented (Huang, 2007). 
Calcium dobesilate has been patented as an active ingredient of its mixed-phase co-
crystaline form. Such co-crystals are based on a theory that the additive(s), which are also 
known as co-crystal formers, are co-crystallized as minor non-stoichiometric components in 
the active agent's crystalline matrix. This co-crystalline phase has then semi-crystalline 
nature and contains a high incidence of crystal defects. Any excess additive that is not co-
crystallized with the active agent forms a separate phase (Additive Phase) apart from the 
active agent, which results in the mixed phase co-crystal composition. The Additive Phase 
and the active agent crystals containing co-crystallized additive can be tightly agglomerated 
forming a mixed phase co-crystal particle. The unique physical properties obtained by this 
process of preparation can include changes in apparent solubility, crystallinity, water 
wetability, dissolution rates, physical powder properties (e.g., bulk density, absolute 
density, refractive index, x-ray diffraction, spectral, flowability, hygroscopicity, adsorption, 
and compaction), bioavailability, apparent permeability, apparent taste, and/or stability 
(Goldman, 2005). Calcium dobesilate is believed to form co-crystals with co-crystal former, 
which has at least one functional group selected from amine, amide, pyridine, imidazole, 
indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and 
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methylsulfanyl, such that calcium dobesilate and co-crystal former are capable of co-
crystallizing from a solution phase under crystallization conditions (Almarsson et al., 2011). 
Calcium dobesilate has also been patented as a component of an ionic liquid (Rogers et al., 
2010) that can be used for overcoming of influence polymorphism in drug substances 
(Rogers et al., 2007). calcium dobesilate can also form solvates with propylene glycol, which 
could be more stable than hydrates (Tawa et al, 2010). However, none of these patents 
contains a particular example of processing of calcium dobesilate. 
3. Activities found in In Vitro and animal models 
3.1 Antioxidant and antiradical activity 
Antioxidant or reduction activity of calcium dobesilate is a result of its hydroquinone 
structure. This was mentioned above in section 2.3 in relationship to its analytical behaviour 
(compare Fig. 8) but this type of reactivity has also an important impact to its biological 
activity. The ability of 2,5-dihydroxybenzenesulfonic acid salts to reduce mercurous and 
silver nitrates to metallic mercury and silver respectively was first observed by Seyda 
(Seyda, 1883).  Calcium dobesilate was shown to actively interact with toxic superoxide 
anion radical O2°-.This reactive oxygen species (ROS) was generated either by UV 
irradiation of an aqueous solution of glycyltryptohphan at 280 nm, or by irradiation of a 
mixture of glycyltryptophan with riboflavine with visible light. Thus calcium dobesilate 
showed the activity similar to that of superoxide dismutase (Lozovskaia et al., 1990). This 
result was confirmed in the experiment in which superoxide radicals were generated in the 
system xanthine/xanthine oxidase/ferrous chloride, but potency of calcium dobesilate to 
scavenge superoxide radicals was 23 times less than that of rutin that was used for 
comparison. However, calcium dobesilate was as potent as rutin in scavenging hydroxyl 
radicals generated in vitro via the iron-catalyzed Haber-Weiss reaction from superoxide 
anion (IC50 = 1.1 vs 0.7 M, respectively). In human erythrocytes, calcium dobesilate 
reduced phenazine methosulfate dependent lipid peroxydation, although the effect was 
observed at high concentration (Brunet et al., 1998a). Oral treatment with calcium dobesilate 
significantly protected diabetic rat retina against a free radicals mediated injury induced by 
ischemia/reperfusion. This was observed in an in vivo experiment with streptozotocin-
induced diabetic rats (Szabo et al., 2001). The results of these experiments support the 
hypothesis that the antioxidant properties of calcium dobesilate could play a role in its 
angioprotective properties in vivo. The antioxidant effects of calcium dobesilate were further 
investigated in relation to the oxidative status, apoptosis and in vitro proliferation of human 
peripheral blood mononuclear cells (PBMC) isolated from healthy donors. Calcium 
dobesilate alone did not modify cell growth in vitro until 10 μM. This molecule counteracted 
oxidative damages generated by the high reducing aldose 2-deoxy-D-ribose (dR). PBMC 
incubated with the reducing sugars D(-)-ribose and 2-deoxy-D-ribose (dR) exhibited 
characteristic patterns of apoptosis, such as DNA fragmentation and morphological 
changes, which can be prevented by exogenous antioxidants such as N-acetyl-L-cysteine  
(Barbieri et al., 1994) and/or other agents (Anderson et al., 1994). Calcium dobesilate was 
shown to reduce apoptosis by delaying both membrane permeability changes and DNA 
fragmentation. Calcium dobesilate 10 μM affected in a time-dependent dynamics several 
parameters representative of the cellular oxidative status. In particular, calcium dobesilate 
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significantly increased the activity of glutathione S-transferase (GST) after three days of 
treatment and also, but to a lower extent, the activity of -glutamyltransferase (-GT). Both 
enzymes are known to be involved in the glutathione (GSH) metabolic cycle. This enzymatic 
behaviour was reversed at seven days of treatment, with a significant GST decrease and a -
GT activation. After seven days of calcium dobesilate exposure, the intracellular GSH 
content was enhanced and this resulted in a dramatic decrease in lipid peroxidation, 
underlining the powerful antioxidant properties of calcium dobesilate in human PBMC. 
(Graber et al., 1998). These results indicate that in vitro antioxidant effects of calcium 
dobesilate manifest in vivo by reduced lipid peroxidation and contribute to the prevention of 
apoptosis.  
3.2 Angioprotective action of calcium dobesilate against reactive oxygen species-
induced capillary permeability 
Microvascular permeability seems to be strongly increased by ROS generated in situ. In an in 
vivo experiment in rats, calcium dobesilate administered intraperitoneally (i.p.), 
intravenously (i.v.) and orally (p.o.) significantly reduced microvascular permeabilization 
induced by ROS in the rat peritoneal cavity. ROS were generated again either with the 
system xanthine / xanthine oxidase or with PMS/NADH. Microvascular permeabilization 
was quantified by Evans blue extravasation. The activity of calcium dobesilate was 
comparable to that of rutin (Brunet et al., 1998b). 
3.3 Enhancement of nitric oxide synthase activity in endothelial cells 
The term endothelium-derived relaxing factor  was originally proposed by Robert Furchgott 
for a then unknown factor leading to relaxation of the smooth muscle of large arteries in 
response to acetylcholine. Nitric oxide NO, which is in fact a free radical, was later found to 
be the mediator of this response. Most of NO in the body is synthesized by the endothelial 
isoform of NO synthase (NOS) from its precursor L-arginine (Palmer et al., 1988a), which is 
inhibited by false substrates of NOS, e.g., L-NG-monomethyl arginine (L-NMMA) (Palmer et 
al., 1988b). NOS is a highly regulated protein and the endothelial form (eNOS) is 
predominantly found in endothelial cells. In them, two different isoenzymes can be 
expressed, depending on the activation state of these cells. In resting, non-activated 
endothelial cells a constitutive enzyme (ecNOS) is expressed (Moncada & Higgs, 1993) and 
after challenge with proinflammatory cytokines and/or bacterial endotoxin a cytokine-
inducible enzyme (iNOS) is expressed in addition (Suschek et al., 1993). The constitutive, 
calcium-dependent isoenzyme produces low amounts of NO for short periods of time 
(Palacios et al., 1989). This endothelium-derived NO plays a crucial role in blood pressure 
regulation (Rees et al., 1989), in inhibition of platelet aggregation and platelet adhesion 
(Radomski et al., 1987a, b), and in modulating leukocyte adhesion, an essential step early in 
tissue inflammation (Kubes et al., 1991, Zimmerman et al., 1992). The inducible, cytosolic, 
calcium-independent NO synthase is expressed only after cell activation and releases large 
amounts of NO for longer periods of time that functions as cytotoxic and immune 
regulatory effector molecule (Kröncke et al., 1995). Diabetes-induced vascular function 
abnormalities are besides other biochemical and morphological changes also reflected by 
decreased synthesis of NO (Durante et al., 1988, McVeigh et al., 1992). Magnesium  2,5-
dihydroxybenzenesulfonate or magnesium dobesilate was used instead of calcium 
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dobesilate in an experiment concerned with investigation of influence of dobesilate on NOS 
activities. The reason of usage of this compound was to eliminate a direct activation of the 
constitutive calcium-dependent NOS by calcium ions. In search for an effect on endothelial 
NO production, macrovascular endothelial cells from rat aorta, microvascular endothelial 
cells from rat exocrine pancreatic tissue, and capillary endothelial cells from rat islets, 
werecultured in the presence or absence of magnesium dobesilate. The activity of ecNOS in 
resident cells as well as of iNOS in cytokine-activated cells was measured indirectly by 
recording the citrulline concentrations in culture supernatants. In each of the different 
endothelial cells magnesium dobesilate incubation (0.25 ± 1 mM) for 24 h led to a significant 
and concentration-dependent increase in ecNOS-activities. With cytokine-activated 
endothelial cell cultures only moderate effects were observed with little or no concentration-
dependency. Addition of the NOS-inhibitor L-NMMA led to a significant suppression of 
citrulline formation in all cultures as an evidence for the enzyme specificity of these effects. 
Both iNOS- and ecNOS-specific reverse transcription and semi-quantitative polymerase 
chain reaction (RT-PCR) with RNA from resident or cytokine-activated endothelial cells 
gave no evidence for an increase in NOS-specific mRNA after MgD-treatment. Furthermore, 
dobesilate-mediated enhancement of NO synthesis in resting endothelial cells was not due 
to iNOS induction in these cells, as no iNOS-specific signal was found by RT-PCR (Suschek 
et al., 1997). Results of these experiments were supported by an additional study in which 
calcium dobesilate was found to enhance the endothelium-dependent relaxation induced by 
acetylcholine in rabbit isolated aorta artery. This effect was clearly endothelium dependent 
because, after the endothelium had been removed, the effect disappeared. The experiments 
were carried out on approximately 2 – 3 wide rings prepared by cutting of the arteries. The 
effect of calcium dobesilate was inhibited when the rings were incubated with increasing 
concentration of another known NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME), 
and this effect was reversed wit L-arginine, the substrate in NO synthesis (Ruiz et al., 1997). 
3.4 Influence of calcium dobesilate on apoptosis in vessel and other tissues 
Since apoptosis is closely linked with oxidation stress some aspects of anti-apoptic effects of 
calcium dobesilate were mentioned above in section 3.1. In a clinical study, the influence of 
calcium dobesilate to apoptosis of varicose veins in comparison with diosmin-hesperidin 
combination was investigated. Patients were treated either with calcium dobesilate or with 
diosmin-hesperidin six weeks prior to the surgical removal of the particular varicose vein. 
Tissue samples obtained from such veins of 56 patients were immunohistochemically 
stained with antibodies of anti-bcl-2 and anti-bax thus aimed at anti-apoptic (bcl-2) and pro-
apoptic (bax) proteins. Significant differences in the presence of bcl-2 protein expression 
between the untreated patient group and the group treated with calcium dobesilate suggest 
that calcium dobesilate could be of benefit in treatment of vascular disorders by down-
regulating apoptosis (Iriz et al., 2008). On the other hand, calcium dobesilate is capable to 
elicit growth arrest of some types of cancer, in particular glioma (Cuevas et al., 2005) and 
basal cell carcinoma (Cuevas  Arrazola, 2005), and induce apoptosis of their cells. 
3.5 Effects of calcium dobesilate on expression of adhesion molecules ICAM-1 and 
VCAM-1 
Diabetes causes metabolic and physiologic abnormalities in the retina, and inflammation 
seems to play a critical role in the development of diabetic retinopathy. Those changes 
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include the upregulation of inducible NOS, cyclooxygenase-2, intercellular adhesion 
molecule-1 (ICAM-1), caspase-1, vascular endothelial growth factor (VEGF), and nuclear 
factor kappa B (NF-κB), which leads to increased production of NO, prostaglandin E2, and 
cytokines (Adamis & Berman, 2008, Kern, 2007). It has also been demonstrated that the 
adhesion of leukocytes to retinal vessels is increased in the retinas of diabetic animals, and 
this increase is correlated with changes in tight junction proteins and increased blood–
retinal barrier (BRB) permeability (Barber et al., 2000, Klaassen et al., 2009). The increase in 
leukostasis is also associated with an increase in the expression of ICAM-1 by retinal 
endothelial cells (Miyamoto et al., 1999). NF-κB regulates the expression of adhesion 
molecules, such as ICAM-1, and NF-κB activation has been correlated with the increase in 
leukostasis and BRB breakdown in diabetic rat retinas (Joussen et al., 2002). In a study on  
streptozotocin-induced diabetic rats, diabetes increased the BRB permeability and retinal 
thickness. These changes were inhibited by Calcium dobesilate treatment. Calcium 
dobesilate also inhibited the increase in leukocyte adhesion to retinal vessels or endothelial 
cells and in ICAM-1 levels, induced by diabetes or elevated glucose. Moreover, CaD 
decreased oxidative stress and p38 mitogen-activated protein kinase (p38 MAPK) and NF-
κB activation caused by diabetes. Thus, calcium dobesilate can prevent the BRB breakdown 
induced by diabetes, by restoring tight junction protein levels and organization and 
decreasing leukocyte adhesion to retinal vessels. The protective effects of calcium dobesilate 
probably involves the inhibition of p38 MAPK and NF-κB activation, possibly through the 
inhibition of oxidative/nitrosative stress (Leal et al., 2011). 
Vascular cell adhesion molecule-1 (VCAM-1) is also an important marker of the 
endothelial function. Similarly to ICAM-1, the concentration of its soluble form (sVCAM-
1) is elevated in diabetes and diabetic retinopathy (Nowak et al., 2008, Clausen et al., 
2000). The influence of calcium dobesilate on the levels of sVCAM-1 and sICAM-1 was 
investigated in a clinical trial in mildly obese male smokers. Endothelial dysfunction in 
these subjects was confirmed by means of increased levels of sVCAM-1, sICAM-1 and 
related parameters, but no effect of calcium dobesilate on levels of cell adhesion molecules 
was observed after 3 months of treatment with  with 1000 mg calcium dobesilate 
dobesilate daily(Schram et al., 2003). 
3.6 Angiogenesis inhibition 
Calcium dobesilate was investigated for its ability to interfere with the process of 
angiogenesis in a mouse gelatine sponge assay using acidic fibroblast growth factor (aFGF) 
as an inducer of neovascularization. According to the reported results, calcium dobesilate 
remarkably reduced vessel ingrowth in aFGF-containing subcutaneous sponges in mice. 
These findings suggest that calcium dobesilate could be an effective agent in the treatment 
of angiogenesis-dependent diseases involving FGFs (Cuevas et al., 2005). This knowledge 
was successfully used in the treatment of erythematotelangiestatic rosacea, which is 
characterized by uncontrolled angiogenesis (Cuevas & Arrazola, 2005). Angiogenesis is, 
however, recently considered to be a main contributor to the pathogenesis of diabetic 
retinopathy (Aiello, 2003,Campochiaro, 2000; Campochiaro and Hackett, 2003). The anti-
angiogenic effect of calcium dobesilate can also be mediated by aminopeptidases inhibition, 
namely by inhibition of aminopeptidase N (Yang et al., 2007). 
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3.7 Reduction of retinal albumin leakage by calcium dobesilate 
The action of calcium dobesilate on retinal albumin leakage in streptozotocin-diabetic rats was 
investigated together with relevant in vivo retinal antioxidant and permeability markers, i.e., 
carboxymethyl-lysine-advanced glycation end product (CML-AGE) formation and vascular 
endothelial cell growth factor (VEGF) overexpression. Twenty days after streptozotocin 
administration, diabetic rats were treated for 10 days with calcium dobesilate (100 mg/kg/day 
per os) or vehicle. Retinal albumin leakage, CML-AGE formation, and VEGF overexpression 
were evaluated by immunohistochemistry of frozen eye sections. Diabetic rats exhibited 
dramatic increases in retinal albumin leakage (31% of positive vessels vs. 0.2% in nondiabetic 
rats, CML-AGE retinal occurrence (40±3% vs. undetectable positive vessels), and retinal VEGF 
protein expression (14.6±1.1 vs. 3.5±0.5 VEGF-positive spots/field). Calcium dobesilate 
significantly reduced retinal albumin leakage (by 70%), retinal CML-AGEs contents (by 62%), 
and retinal VEGF expression (by 69.4%). In conclusion, calcium dobesilate orally given to 
diabetic rats markedly reduced retinal hyperpermeability, CML-AGE contents, and VEGF 
overexpression. These results strongly suggest that calcium dobesilate stabilizes blood–retinal 
barrier in diabetic retinopathy (Rota et al., 2004). 
3.8 Influence of calcium dobesilate on platelets and blood viscosity 
Platelet-active drugs are in general of potential benefit in the prevention of diabetic 
microangiopathy. Calcium dobesilate was shown to reduce aggregation and the release 
reaction induced by thrombin and collagen in rabbit platelets (Michal  Gotti, 1988). 
Calcium dobesilate also increased platelet cAMP concentrations in vitro and ex vivo probably 
through activation of adenylate cyclase (Michal and Gotti, 1988). In addition, this drug 
reduced platelet electrophoretic mobility (Heidrich et al., 1983), and it inhibited, in a time- 
and concentration-dependent manner, platelet-activating factor (PAF) production by the 
EA926 endothelial cell line stimulated by thrombin (Bussolino et al., 1986). The effects of 
PAF on the microvasculature bed of glomerular or pulmonary microcirculation suggest that 
PAF might play a role in microcirculation disease. The rheological properties of blood in 
diabetes mellitus have received increasing attention since Skovborg and colleagues 
demonstrated elevation of whole-blood viscosity in diabetics (Skovborg et al., 1966). In 
particular, evidence has accumulated that abnormal blood viscosity plays a role in the 
pathogenesis of diabetic retinopathy. Increased blood viscosity in diabetes mellitus has been 
attributed to changes in plasma protein composition (Barnes et al., 1977, Hoare et al., 1976, 
Hudomel et al., 1977,  Skovborg et al., 1966); and to increased aggregation of red blood cells 
(McMillan, 1976). The mechanism by which hyperviscosity contributes to the deterioration 
of the microcirculation in the retina and other organs in diabetics is that, by increasing the 
resistance to blood flow, it causes blood stasis, especially in the capillaries and postcapillary 
venules, which are the sites where the very early lesions of diabetes microangiopathy 
characteristically appear. In some studies, calcium dobesilate has been demonstrated to 
decrease hyperviscosity in blood (Barras  Graf, 1980, Vojnikovic, 1991), perhaps through a 
fibrinogen-lowering effect (Barras  Graf, 1980, Vinnazzer  Hachen, 1987). 
3.9 Influence of calcium dobesilate on plasma levels of endothelin 
Endothelin-1 (ET-1) was discovered by Yanagisawa and colleagues in 1988 (Yanagisava et 
al., 1988) in the supernatant of aortic endothelial cells. ET-1 is a potentand prolonged 
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vasoconstrictor and mitogenic endothelium derived peptide, and has been considered as a 
marker for endothelial damage and potential contributor to the developmentof the 
atherogenic process. Increased circulating ET-1 levels was found in patients with 
atherosclerosis, as well as in patients with Type 2 diabetes mellitus suggesting arole in the 
pathogenesis of these disorders (Ak et al., 2001). Plasma ET-1 plays also an important role in 
the whole patho-physiological process of diabetic retinopathy. Its plasma concentrations 
correlate to the severity of the disease, measures of their plasma concentrations can help to 
predict the severity of the disease. They also enable to distinguish between proliferative and 
non-proliferative diabetic retinopathy (Cao et al., 2009). In a clinical study, the plasma ET-1 
concentrations were determined in 45 diabetes mellitus patients. The changes of ET-1 in 20 
diabetic retinopathy patients before and after treatment with calcium dobesilate and 30 
normal controls were observed. The level of plasma endothelin was higher in diabetes 
mellitus patients than that of the controls, which was even higher in diabetic retinopathy. 
After treatment with calcium dobesilate, the plasma ET-1 level decreased significantly 
(Zhong  Guo, 1997). 
4. Pharmacokinetics and metabolism of calcium dobesilate 
Studies on the metabolism and pharmacokinetics of calcium dobesilate were  carried out by 
Benakis and colleagues (Benakis et al., 1974). They reported the results of blood levels of 
calcium dobesilate labeled with 35S isotope, protein binding and urinary excretion in 
humans. The studies in humans were performed by the administration of the drug p.o. or i.v. 
After i.v. medication, 500 mg, the maximum value is obtained 5 min after administration 
and is about 65 mg/ml. This value of dicreases rapidly, the plasma half-life being 1 hr. After 
administration by the oral route, 500 mg in a capsule, the maximum value was obtained at 
the 6th hour after medication and is about 8mg/ml, and a plateau was obtained between the 
3rd and the 10th hour. Levels decreased slowly and were undetectable 24 hours after 
administration. Intestinal absorption was 15% per hour during the first 7 hours and then 
decreased to 5% per hour. More than 80% of the drug is absorbed in the first 8 hours. The 
drug is 20–25% protein bound. The specific affinity of the drug to aggregated and 
nonaggregated platelets has been demonstrated. Calcium dobesilate does not cross the 
blood-brain barrier. Urinary elimination in the first 24 hours reaches 75% after i.v. 
medication and 50% after oral medication. 
5. Clinical findings and usage of calcium dobesilate in prevention and 
treatment of diabetic retinopathy 
5.1 Results of clinical studies 
While the results of various in vitro experiments suggest that calcium dobesilate would have 
to be effective in the treatment of diabetic retinopathy, the results of clinical trials are 
ambiguous. One of the first clinical studies was a double-blind, randomized trial, which 
lasted for 2 years. The authors investigated the efficacy of calcium dobesilate on diabetic 
retinopathy in 51 patients, 17 were on placebo. The statistical analysis of the results 
indicated that calcium dobesilate acts as a potent angioprotector, capable of preventing both 
intra. and extraretinal hemorrhages. The drug also lowered the incidence of exudate 
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formation and improved visual acuity (Salama Benarroch et al., 1977). A double-blind cross-
over clinical trial performed on 18 diabetics, the results of which were published in the same 
year, investigated the effect of calcium dobesilate on capillary resistance and background 
retinopathy in comparison with placebo. Each treatment lasted 8 months. The study gave no 
evidence of a significant beneficial effect of calcium dobesilate on the capillary resistance in 
diabetics or on the course of the diabetic retinopathy (Larsen et al., 1977). The additional two 
independent, double-blind, controlled studies were performed to evaluate the efficacy of 
calcium dobesilate for the treatment of nonproliferative diabetic retinopathy. In the first 
suty, forty-two patients underwent a six-month crossover evaluation while receiving 
calcium dobesilate (750 mg per day) and placebo in random order. In the second ome, 
thirty-six patients received calcium dobesilate (1,000 mg per day) or placebo for one year. 
Evaluation by clinical examination, fluorescein angiography, angiography, and fundus 
photography failed to demonstrate any beneficial effect of calcium dobesilate (Stamper et 
al., 1978).  On the other hand, the study with 50 patients who had diabetic retinopathy open-
angle glaucoma, raised intraocular pressure, and hyperviscosity of whole blood, plasma, 
and aqueous humor and received 1,500 mg of calcium dobesilate daily for 3 months or 
pacebo exhibited the significant improvement of the state of the retina, the visual acuity, the 
intraocular pressure and the 3 viscosity values in the calcium dobesilate group (Vojnikovic, 
1984). In a retrospective controlled study, 54 patients with diabetic retinopathy received 
calcium dobesilate (mean 650 mg/day) for 6-30 months (mean 18 months) and were 
compared to a correspondingly selected control group. The patients were divided into three 
subgroups (mild, moderate, and severe diabetic retinopathy). Microaneurysms, blot 
hemorrhages, striate hemorrhages, and hard exudates were assessed semiquantitatively 
from panorama fundus photographs, using a scoring system. The effect of calcium 
dobesilate was statistically significant for cases with moderate diabetic retinopathy on 
summing up the scores of the various retinal lesions. No effect on diabetic maculopathy or 
visual acuity was observed (Adank & Koerner,  1985). A more recent study, however, 
carried out in 197 patients, showed that 2 g of calcium dobesilate daily for 2 years had 
exhibited a significantly better activity than placebo on prevention of BRB disruption, 
independently of diabetes control. Tolerance was very good (Ribeiro et al., 2006). One of the 
most recent studies was concerned with the infuence of calcium dobesilate on development 
of clinically significant macular oedema (CSME) within a follow-up period of 5 years. It was 
performed on 635 patients from 40 centers in 11 countries. They were treated with 1500 mg 
of calcium dobesilate per day in three divided doses of 500 mg or with placebo for period up 
to 5 years. Unfortunately, this trial showed that calcium dobesilate did not reduce the risk of 
development of CSME (Haritoglou et al., 2009). 
6. Safety and important adverse effects of calcium dobesilate 
Adverse events with calcium dobesilate do not occur very frequently and have the following 
distribution in terms of frequency: fever (26%), gastrointestinal disorders (12.5%), skin 
reactions (8.2%), arthralgia (4.3%), and agranulocytosis (4.3%). No deaths have been 
attributed to calcium dobesilate. Most adverse events are rare and unrelated to the 
pharmacological properties of calcium dobesilate. (Allain et al., 2004). Agranulocytosis, 
which was first reported in 1992 (Kulessa et al., 1992), is probably the most serious adverse 
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effect of calcium dobesilate. The estimated prevalence of agranulocytosis is 0.32 
cases/million treated patients, i.e. ten times less than the calculated prevalence of 
agranulocytosis in the general population (Allain et al., 2004). Moreover, there is no case 
report that would attribute agranulocytosis clearly to calcium dobesilate during a simple 
treatment of diabetic retinopathy. 
7. Dosage and aplication forms of calcium dobesilate 
Calcium dobesilate is predominantly administered p.o. in uncoated tablets. Initial dosage in 
early stages of microangiopathies, namely diabetic retinopathy, is 250 mg calcium dobesilate 
three times a day (three tablets per day). After 2-3 weeks it is possible to decrease dosage to 
the keeping level 250-500 mg calcium dobesilate per day. Diminished performance of liver 
or kideys has no impact to dosage of calcium dobesilate (Medicinal products database of the 
State institute for Drug Control, 2011). 
7.1 Intraocular preparations of calcium dobesilate 
Except of usually administerd oral tablets, some topic preparations of calcium dobesilate 
have also been reported. Ocular preparations for a local treatment of diabetic retinopathy 
and related disorders like glaucoma are the matter of the patent application of Velpandian 
(Velpandian, 2006). The simpliest eye solution, which is the Composition I of the Example 1 
of this patent, contain 1 % weight-volume (w/v) calcium dobesilate, 0.76 % w/v sodium 
chloride for isotonisation and 0.1 % w/v sodium metabisulfite as an antioxidant. The 
Composition II is similar but contains only 0.70 % w/v sodium chloride and furtherly 0.4 % 
w/v hydroxypropylmethylcellulose as an viscosity-increasing agent. The Compositions III a 
IV are water insoluble and water soluble eye oitments respectively. The micronized form of 
calcium dobesilate in concentration 1 % w/v is used for preparation of both. The vehicle for 
water insoluble oitment is the white petrolatum mixed with a mineral oil, for the water 
soluble one it is a mixture of polyethylene glycols. Both oitments contain suitable 
antimicrobial preservatives in concentration 0.01 % w/v and 0.001 % w/v respectively. The 
composition V is a controlled-release gel based on a suitable gel-forming polymer and 
contain also 1 % w/v calcium dobesilate. 
8. Conclusion  
Calcium dobesilate is one of the oldest drugs used in the treatment of diabetic retinopathy. 
The first reports concerning its usage appeared in the late 1960th (Sevin & Cuendet, 1969a, 
b). Its mechanisms of action have been gradually elucidated. Many of them are related to its 
reactivity as a reducing agent. Now it is known that they include lowering of reactive 
oxygen species-induced capillary permeability, enhancement of nitric oxide synthase 
activity in endothelial cells, influence of calcium dobesilate on apoptosis in vessel and other 
tissues, effects of calcium dobesilate on expression of cellular adhesion molecules, 
angiogenesis inhibition, reduction of retinal albumin leakage, influence of calcium 
dobesilate on platelets and blood viscosity, influence of calcium dobesilate on plasma levels 
of endothelin and others. Despite certain doubts of its efficiency originating from results of 
some clinical trials calcium dobesilate still remains the only angioprotective agent that 
reduces the progression of diabetic retinopathy (Garay et al., 2005).  
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